Genmab Shares Surge 29% to Record High on Cancer Trial Data
U.S.-listed shares rose 29% to $57.52 after trial data showed an experimental cancer therapy cut patient mortality risk by half.
Story updates
05:24:41 PM UTC
SquawkNews
Shares of Genmab (GMAB) surged nearly 30% to an all-time high on Wednesday after the drugmaker announced promising Phase 3 results for its experimental head and neck cancer treatment.GMAB stock recorded its biggest single-day gains ever and is heading for its best-ever month.What Did The Phase 3 Tr…
By Mackenzie TatananniGenmab shares rocketed toward their best session on record Wednesday after trial data showed an experimental cancer therapy slashed the risk of patient mortality in half.U.S.-listed shares of the Danish drugmaker surged 29% to $57.52, and were pacing toward their highest close…